Blood markers to help diagnose acute mesenteric ischemia
Official title: Evaluation of the Discriminative Abilities of Biomarkers for the Diagnosis of Acute Mesenteric Ischemia Compared With Another Similar Clinical Presentation: a Pilot Study
Run by Assistance Publique Hopitaux De Marseille · NCT06869564 · Data updated 2026-11-12
We will test whether measuring adenosine deaminase in blood helps doctors quickly diagnose acute mesenteric ischemia in adults who come to hospital with severe unexplained abdominal pain.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 130 (estimated) |
| Sponsor | Assistance Publique Hopitaux De Marseille Academic / other |
| Locations | 1 site (Marseille) |
| Status | Recruiting |
| Started | June 29, 2025 |
| Main results expected | January 1, 2027 |
| Study ends | February 1, 2027 |
| Registry record updated | September 23, 2026 |
| Trial ID | NCT06869564 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older who present with severe unexplained abdominal pain and have an indication for a contrast abdominopelvic CT to rule out suspected acute mesenteric ischemia, are affiliated with the French social security system, and can give written non-opposition are ideal candidates.
✕Probably not a fit
Patients with acute myocardial ischemia (which can raise adenosine deaminase), those unable to read French or give consent, and legally protected persons excluded under French law are unlikely to benefit or to be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot interventional study collects blood samples from adults presenting with severe unexplained abdominal pain who are undergoing contrast-enhanced abdominopelvic CT to rule out acute mesenteric ischemia (AMI). Investigators measure soluble plasma adenosine deaminase activity and lymphocyte-bound adenosine deaminase, then compare biomarker levels between patients with CT-confirmed AMI and those with similar clinical presentations without AMI. The primary goal is to determine the discriminatory capacity (sensitivity and specificity) of these ADA measurements for earlier diagnosis, since standard markers like lactate often rise late. The study enrolls adults including pregnant and breastfeeding patients and is conducted at Timone Hospital in Marseille according to French consent regulations.
Why it matters
Potential benefit: If successful, this biomarker could help doctors diagnose AMI earlier, potentially enabling timelier revascularization and reducing mortality and bowel loss.
How similar studies have gone: Adenosine deaminase has been reported in myocardial ischemia, but using ADA as a biomarker specifically for acute mesenteric ischemia is novel and unproven in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female, 18 years of age or older * with an indication (hyperintense abdominal pain with no obvious diagnosis other than acute mesenteric ischemia) for an injected abdominopelvic scan for hyperintense abdominal pain suspected of acute mesenteric ischemia * Including pregnant or breast-feeding women, as this is a risk factor for AMI in young subjects * Affiliated with the French social security system * Able to express non-opposition in writing Exclusion Criteria: * Presenting acute myocardial ischemia, to avoid biasing the levels of the biomarkers studied (increased in this clinical situation) * Patient in a period of exclusion from another research protocol at the time the non-opposition is signed, * Person protected by articles L1121-6 and L1121-8 of the French Public Health Code (deprived of liberty by court order, socially vulnerable, adult incapable or unable to express non-opposition). * Persons who are unable to read and understand the French language sufficiently to give their consent to participate in research.
Where it's running
-
Timone hospital
Marseille, France Recruiting
Study contacts
- Study coordinator: Diane Mège
- Email: promotion.interne@ap-hm.fr
- Phone: 0491435817
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Predictors of transmural NOMI in ICU patients with suspected acute mesenteric ischemia
This study looks at ICU patients with suspected acute mesenteric ischemia to see which factors best predict transmural non-occlusive mesenteric ischemia.
-
Life after acute mesenteric ischemia
See how adults treated for acute mesenteric ischemia at Strasbourg University Hospitals between 2010 and 2022 are doing in terms of quality of life.
-
Oral antibiotics for treating acute mesenteric ischemia
This study is testing if giving oral antibiotics to patients with acute mesenteric ischemia can help them survive better and avoid surgery.
-
Identifying biomarkers for acute intestinal ischemia
This study is trying to find new markers in the blood that can help doctors quickly diagnose acute intestinal ischemia in patients.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.